

Substitute for form 1449A-PTO

NOV 02 2004

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	09/646,478
Filing Date	March 4, 2002
First Named Inventor	Jin Jen
Art Unit	1642
Examiner Name	Rawlings, Stephen L.

Attorney Docket Number

GZ 2018.00

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number – Kind Code ² (if known)			
SIR	1	US-5,734,039	03-31-98	Calabretta et al.	
	2	US-			
	3	US-			
	4	US-			
	5	US-			
	6	US-			
	7	US-			
	8	US-			
	9	US-			
	10	US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ – Number ⁴ – Kind Code ⁵ (if known)				
SIR	11	WO 99/50278	10-07-99	Beaudry et al.		
	12					
	13					
	14					
	15					
	16					
	17					
	18					
	19					
	20					

Examiner's Signature

[Signature]

Date

Considered

10/14/05

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2.0 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	1	of	1		Complete if Known
				Application Number	09/646,478
				Filing Date	March 4, 2002
				First Named Inventor	Jin Jen
				Art Unit	1642
				Examiner Name	Rawlings, Stephen L.
				Attorney Docket Number	GZ 2018.00

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published
SJR	1	DHILLON, A.P. et al., "Neural markers in carcinoma of the lung" (1985) <i>Br. J. Cancer</i> 51:645-652
	2	GOLAY, J. et al., "Expression of A-myb, But Not c-myb and B-myb, Is Restricted To Burkitt's Lymphoma, Sig+ B-Acute Lymphoblastic Leukemia, and a Subset of Chronic Lymphocytic Leukemias" (1996) <i>Blood</i> 87:190-1911
	3	HIBI, et al., "Serial Analysis of Gene Expression in Non-Small Cell Lung Cancer" (1991) <i>Cancer Research</i> 58:5890-5894
	4	HOJO, S., et al., "Overexpression of p53 protein in interstitial lung diseases" (1998) <i>Respiratory Medicine</i> 92:184-190
	5	KASAI, K. et al., "Pulmonary Large Cell Carcinoma Expressing Neuroendocrine Markers: The Morphological, Biological, and Neuroendocrine Features of Their Cell Lines and Surgical Cases" (1992) <i>Jpn. J. Cancer Res.</i> 83:1002-1010
	6	MOOI, W.J., et al., "Non-small cell lung carcinomas with neuroendocrine features. A light microscopic, immunohistochemical and ultrastructural study of 11 cases" (1988) <i>Histopathology</i> 13:329-337
	7	ROSENWALD, I.B. "Upregulated expression of the genes encoding translation initiation factors eIF-4E and eIF-2alpha in transformed cells" (1996) <i>Cancer Letters</i> 102:113-123
	8	SALGIA, R., et al. "Molecular Abnormalities in Lung Cancer" (1998) <i>J. of Clinical Oncology</i> 16:1207-1217
	9	WANI, G., et al. "Enhanced expression of the 8-oxo-7, 8-dihydrodeoxyguanosine triphosphatase gene in human breast tumor cells" (1998) <i>Cancer Letters</i> 125:123-130
	10	Partial European Search Report dated July 29, 2004
	11	
	12	
	13	
	14	
	15	
	16	
	17	
	18	

Examiner's Signature	1 ~	Date Considered
		10/14/05

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. This information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 and select option 2.